Strong traction in key markets, new product launches and reduced cost resulted in a good quarter for Glenmark | Glenmark Pharmaceuticals Q2 FY23 Result & Earning Call Highlights
Strong traction in key markets, new product launches and reduced cost resulted in a good quarter for Glenmark | Glenmark Pharmaceuticals Q2 FY23 Result & Earning Call Highlights
Strong traction in key markets, new product launches and reduced cost resulted in a good quarter for Glenmark | Glenmark Pharmaceuticals Q2 FY23 Result & Earning Call Highlights
Published on 16 November 2022 .Views 11.Comments 0